Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition

Hypertension

Volumn 35, Issue 2, 2000, Pages 602-608

  Loichot, Cécile ^a   Cazaubon, Catherine ^c   Grima, Michèle ^a   De Jong, Wybren ^a   Nisato, Dino ^c   Imbs, Jean Louis ^a,b   Barthelmebs, Mariette ^a,d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c SANOFI   (France)

^d Roche Inst de Pharmacologie Clin   (France)

Author keywords

Hemodynamics; Hypertension, experimental; N(G) nitro L arginine); Receptors, vasopressin; SR 49059

Indexed keywords

ALBUMIN; CREATININE; N(G) NITROARGININE; NITRIC OXIDE; RELCOVAPTAN; UREA; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HEART RATE; HEART WEIGHT; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY MASS; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RAT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE;

EID: 0033963447     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.2.602     Document Type: Article

References (36)

1. Palmer RM, Fertige AG, Moncada S. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature. 1987; 327:524-526.
2. Bank N, Aynedjian HS, Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension. 1994; 24:322-328.
3. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension. 1998;32:958-964.
4. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension. 1993;21:660-666.
5. ω-nitro-L-arginine methyl ester. Hypertension. 1997;30: 64-70.
6. Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL. Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996;314:325-332.
7. Garcia-Villalon AL, Garcia JL, Fernandez N, Monge L, Gomez B, Dieguez G. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol. 1996;118:1848-1854.
8. G-Monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol. 1992;262:R1137-R1144.
9. G-nitro-L-arginine methyl ester or indomethacin on differential regional and cardiac haemodynamic actions of arginine vasopressin and lysine vasopressin in conscious rats. Br J Pharmacol. 1991;102:65-72.
10. Hirata Y, Hayakawa H, Kakoki M, Tojo A, Suzuki E, Nadata D, Kimura K, Goto A, Kikuvhi K, Nagano T, Hirobe M, Omata M. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney. Hypertension. 1997;29:58-64.
11. Calka J, Block CH. Relationship of vasopressin with NADPH-diaphorase in the hypothalamo-neurohypophysial system. Brain Res Bull. 1993;32: 207-210.
12. Liu QS, Jia YS, Ju G. Nitric oxide inhibits neuronal activity in the supraoptic nucleus of the rat hypothalamic slices. Brain Res Bull. 1997; 43:121-125.
13. Lutz-Bucher B, Koch B. Evidence for an inhibitory effect of nitric oxides on neuropeptide secretion from isolated neural lobe of the rat pituitary gland. Neurosci Lett. 1994;165:48-50.
14. Cao L, Sun X, Shen E. Nitric oxide stimulates both the basal and reflex release of vasopressin in anesthetized rats. Neurosci Lett. 1996;221: 49-52.
15. Noguera J, Medina P, Segarra G, Martinez MC, Aldasoro M, Vila JM, Lluch S. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol. 1997;122:431-438.
16. Manning RD, Hu L, Williamson TD. Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. Hypertension. 1994; 23:951-956.
17. 1a receptors. J Clin Invest. 1993;92: 224-231.
18. 1A receptor antagonist, in hypertension induced by chronic inhibition of nitric oxide synthesis. Br J Pharmacol. 1997;122:203P. Abstract.
19. Tolins JP, Shultz PJ. Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt. Kidney Int. 1994;46:230-236.
20. Barthelmebs M, Vailly B, Grima M, Velly J, Stephan D, Froehly S, IMB JL. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats. J Cardiovasc Pharmacol. 1991;18:243-253.
21. Schmidt M, Giesen-Crouse E, Imbs JL. Renal and iliac vascular effects of dopamine in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol. 1987;335:378-384.
22. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
23. Michel B, Grima M, Stephan D, Coquard C, Welsch C, Barthelmebs M, Imbs JL. Plasma renin activity and changes in tissue angiotensin converting enzyme. J Hypertens. 1994;12:577-584.
24. Tourna K, Jouquey S, Hamon G. The endothelial modulation of isolated rat arteries responses to vasopressin and adenosine during aging. Pharmacol Res. 1995;31(suppl):245. Abstract.
25. Deng LY, Thibault G, Schiffrin EL. Effects of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15:527-537.
26. McCulloch AI, Bottrill FE, Randall MD, Hiley R. Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br J Pharmacol. 1997;120:1431-1438.
27. Yoshida M, Kikukawa M, Hisa H, Satoh S. Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8). Br J Pharmacol. 1996;117:885-890.
28. Lauson HD. Metabolism of antidiuretic hormones. Am J Med 1967;42: 713-744.
29. Goyer M, Bui H, Chou L, Evans J, Keil LC, Reid IA. Effect of inhibition of nitric oxide synthesis on vasopressin secretion in conscious rabbits. Am J Physiol. 1994;266:H822-H828.
30. Ota M, Crofton JT, Festavan GT, Share L. Evidence that nitric oxide can act centrally to stimulate vasopressin release. Neuroendocrinology. 1993; 57:955-959.
31. Manning RD Jr, Hu L, Reckelhoff JF. Role of nitric oxide in the arterial pressure and renal adaptations to long term changes in sodium intake. Am J Physiol. 1997;272:R1162-R1169.
32. Gardiner SM, Kemp P, Bennett T, Palmer RMJ, Moncada S. Nitric oxide synthase inhibitors caused sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats. Eur J Pharmacol. 1992; 213:449-451.
33. G-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin. J Pharmacol Exp Ther. 1992;261:240-245.
34. Johnson MD, Kinter LB, Beeuwkes R. Effects of AVP and DDAVP on plasma renin activity and electrolyte excretion in conscious dogs. Am J Physiol. 1979;236:F66-F70.
35. Qiu C, Muchant D, Beierwaltes WH, Racusen L, Baylis C. Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension. 1998;31:21-26.
36. Xu Y, Arnal JF, Hinglais N, Appay MD, Laboulandine I, Bariety J, Michel JB. Renal hypertensive angiopathy: comparison between chronic NO suppression and DOCA-salt intoxication. Am J Hypertens 1995;8: 167-176.